AXA Framlington Biotech Fund Z INC

Name
AXA Framlington Biotech Fund Z INC
Manager
AXA Investment Managers UK Ltd
Type
Unit Trust
ISIN
GB00BRJZVL27
Sector
Specialist
Launched
19/01/2015
OCF
0.83 %
Risk Rating
4
3 Year Sharpe
0.30
3 Year Alpha
-1.02
Yield
0 %
Benchmark
NASDAQ Biotechnology TR USD
The aim of this Fund is to provide long-term capital growth. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Fund may also invest in other transferable securities and units in collective investment schemes. The Fund may use derivatives for Efficient Portfolio Management. Use may be made of borrowing, cash holdings, hedging and other investment techniques permitted in the applicable Financial Conduct Authority rules.
Holding %
Amgen Inc 8.71 %
Alexion Pharmaceuticals Inc 6.62 %
Gilead Sciences Inc 6.59 %
Biogen Inc 6.34 %
Biomarin Pharmaceutical Inc 4.19 %
Vertex Pharmaceuticals Inc 3.70 %
Celgene Corp 3.56 %
Illumina Inc 3.56 %
Takeda Pharmaceutical Co Ltd 3.09 %
Alnylam Pharmaceuticals Inc 2.96 %
Region %
United States 83.65 %
Eurozone 5.54 %
Sector %
Healthcare 99.74 %
Name
AXA Investment Managers UK Ltd
Address
EC1A 7NX, London, United Kingdom
UCITS
Yes
Legal Structure
Unit Trust

Managers

Dani Saurymper
Joined 04/01/2015

Dani Saurymper joined AXA IM in April 2015 as Fund Manager for the AXA Framlington Health Fund. He joined from Barclays Capital where he was a senior equity research analyst covering European healthcare.

Linden Thomson
Joined 07/05/2012

Data provided by Morningstar.

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.